Monitor upcoming clinical trial updates and regulatory filings for signs of accelerated development pace under new CMO leadership. Assess whether pipeline progression improves relative to prior timelines.
Price Chart
Executive Summary
Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026, replacing outgoing CMO Dr. David Mauro. The leadership change is part of a planned transition as the company advances its clinical pipeline, with no accompanying financial updates or material operational changes disclosed.
Key Facts
- Dr. Vicki Goodman will become Chief Medical Officer of Recursion effective April 6, 2026.
- Dr. David Mauro is transitioning out of the CMO role after approximately three years.
- No financial terms, compensation details, or material operational changes were disclosed.
- The company reaffirmed it is on track with previously communicated clinical and regulatory expectations.
- Dr. Goodman brings extensive oncology drug development experience from Mural Oncology, Exelixis, Merck, and Bristol Myers Squibb.
Financial Impact
Minimal near-term financial impact; no disclosed cost or revenue implications.
Risk Factors
- Leadership transition could temporarily slow decision-making in clinical development.
- High expectations for Dr. Goodman may create pressure if pipeline milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $4.05 (−16.88%) |
Oct 15, 2026 12d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.05 (+2.64%) |
Oct 15, 2026 12d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $4.05 (−2.64%) |
Oct 15, 2026 12d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $4.05 (+2.64%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.05 (−12.53%) |
Oct 6, 2026 21d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $4.05 (−12.53%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $4.05 (+2.02%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $4.05 (+26.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers